ONCLIVE NEWS NETWORK: ON LOCATION WILL BE LIVE AT ESMO THIS WEEK - STAY TUNED FOR MORE INFORMATION!

Dr. Brufsky on Challenges Facing Biosimilars in Breast Cancer

Adam M. Brufsky, MD, PhD
Published: Friday, Mar 16, 2018



Adam M. Brufsky, MD, PhD, professor of medicine, associate chief, Division of Hematology/Oncology, co-director, Comprehensive Breast Cancer Center, associate director, Clinical Investigation, University of Pittsburgh, discusses challenges facing biosimilars for the treatment of patients with breast cancer.

An issue with biosimilars is determining the reason for using them, explains Brufsky. One of the main benefits associated with biosimilars is the lower cost compared with other treatments. According to Brufsky, there would have to be cost differentials for physicians to want to use this treatment, as they already have experience with other regimens.

Currently, physicians have the most experience with Zarxio (filgrastim-sndz), which is a biosimilar for the G-CSF analog Neupogen (filgrastim). That has been a required treatment that has to be proven to show a cost benefit for the patient.
 


Adam M. Brufsky, MD, PhD, professor of medicine, associate chief, Division of Hematology/Oncology, co-director, Comprehensive Breast Cancer Center, associate director, Clinical Investigation, University of Pittsburgh, discusses challenges facing biosimilars for the treatment of patients with breast cancer.

An issue with biosimilars is determining the reason for using them, explains Brufsky. One of the main benefits associated with biosimilars is the lower cost compared with other treatments. According to Brufsky, there would have to be cost differentials for physicians to want to use this treatment, as they already have experience with other regimens.

Currently, physicians have the most experience with Zarxio (filgrastim-sndz), which is a biosimilar for the G-CSF analog Neupogen (filgrastim). That has been a required treatment that has to be proven to show a cost benefit for the patient.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Community Practice Connections: Oncology Best Practice™ Targeting Cell Cycle Progression: The Latest Advances on CDK4/6 Inhibition in Metastatic Breast CancerOct 31, 20181.0
Publication Bottom Border
Border Publication
x